---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099413"
form_type: "8-K/A"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:33:47.737819+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# EyePoint completes enrollment in both Phase 3 wet AMD trials for DURAVYU; topline data mid-2026

## Summary
- LUCIA enrolled over 400 patients in 7 months; combined LUGANO and LUCIA total over 800 patients.
- DSMC interim review confirmed safety consistent with prior trials; no protocol changes, continuation recommended.
- Topline 56-week data for LUGANO expected mid-2026; LUCIA topline data to follow shortly after.
- DURAVYU is sustained-release TKI with 6-month redosing; evaluated vs on-label aflibercept in non-inferiority design.
- Phase 3 program aligned with FDA/EMA; NDA filing targeted after one-year efficacy and safety endpoint.

## SEC filing metadata
- accession: 0000950170-25-099413
- form_type: 8-K/A
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025099413/0000950170-25-099413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025099413/eypt-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099413
- JSON: https://secwatch.observer/filing/0000950170-25-099413.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.